Ann: Acrux receives $1.73m advance on FY25 R&D Tax Incentive, page-20

I expect the next quarterly report due on Wednesday to be again abysmal which is why Acrux has borrowed money to keep going.
it would seem that the survival of the company depends on the sales revenue generated from Nitroglycerin ointment 0.4% which should start to be received in the next quarter ie April to June and will be reported in the July quarterly report.
if there is still only 1 competitor as has been previously reported there might be a glimmer of hope that finally meaningful revenue will be received, but this would go against all previous performance.